阿托伐他汀对蒽环类化疗期间主动脉僵硬度的影响:随机临床试验的二次分析
该研究为STOP-CA随机临床试验的二次分析,纳入300例计划接受蒽环类化疗的新诊断淋巴瘤患者,随机接受阿托伐他汀40mg每日一次或安慰剂治疗12个月。结果显示,阿托伐他汀组主动脉弓脉搏波速度(PWV)保持稳定,而安慰剂组升高;
要点
- 阿托伐他汀预处理可减轻蒽环类化疗引起的主动脉僵硬度增加。
- 阿托伐他汀组PWV增加≥1个标准差的风险显著低于安慰剂组(OR 0.05)。
- PWV增加≥1个标准差与左心室射血分数平均下降2.70%相关。
核心结论
- 阿托伐他汀预处理与接受蒽环类化疗的淋巴瘤患者血管功能保护相关。
研究设计与样本
- STOP-CA随机临床试验的二次分析,双盲、安慰剂对照,多中心(美国和加拿大9个学术中心),纳入300例新诊断淋巴瘤患者。
- 干预为阿托伐他汀40mg每日一次或安慰剂治疗12个月。
- 主要终点为心脏磁共振成像衍生的主动脉弓脉搏波速度(PWV)和主动脉扩张性(AD),采用意向性治疗分析。
主要发现
- 阿托伐他汀组PWV保持相似(均值[SD] 6.5[1.9] vs 6.5[2.0] m/s),安慰剂组升高(5.7[1.8] vs 6.8[2.0] m/s) over 12个月。
- 升主动脉扩张性(AAD)下降≥1个标准差(1.8×10-3 mm Hg-1)的比例:阿托伐他汀组6/88(7%),安慰剂组14/80(18%)。
关键数值与推荐
- PWV增加≥1个标准差定义为0.8 m/s。
- AAD下降≥1个标准差定义为1.8×10-3 mm Hg-1。
- PWV增加≥0.15 m/s作为次要终点评估。
临床怎么用
- 对于计划接受蒽环类化疗且无他汀临床指征的淋巴瘤患者,可考虑阿托伐他汀预处理以减缓主动脉僵硬度增加。
- 需结合主要试验结果综合评估他汀在蒽环类心脏毒性预防中的作用。
局限性
- 为事后二次分析,部分终点为探索性。
- 配对PWV数据仅152例,配对AD数据仅168例,样本量有限。
- 研究人群为淋巴瘤患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anthracyclines, which are key to many chemotherapeutic protocols, have been associated with increased vascular stiffness, a major factor associated with cardiovascular morbidity and mortality. There is no evidence-based intervention to prevent anthracycline-associated vascular dysfunction. OBJECTIVE: To investigate whether atorvastatin pretreatment is associated with attenuation of the anthracycline-induced increase in aortic stiffness. DESIGN, SETTING, AND PARTICIPANTS: This study is a secondary analysis of a double-blind, randomized clinical trial (Statins to Prevent the Cardiotoxicity From Anthracyclines [STOP-CA]). Enrollment occurred between January 25, 2017, and September 10, 2021, with the last follow-up on October 10, 2022. Primary analyses were reported on August 8, 2023. STOP-CA was a multicenter trial across 9 academic centers in the US and Canada. Participants were patients with newly diagnosed lymphoma scheduled to undergo anthracycline-based chemotherapy with no clinical indication for a statin. INTERVENTION: Atorvastatin (40 mg, once daily) or placebo for 12 months. MAIN OUTCOMES AND MEASURES: This subanalysis of the STOP-CA trial includes post hoc end points with cardiac magnetic resonance imaging-derived aortic arch pulse wave velocity (PWV) and aortic distensibility (AD). An intention-to-treat approach was applied. The proportions of participants with a 1 SD or more increase in PWV and a 1 SD or more decrease in ascending aortic distensibility (AAD) were calculated in each group over 12 months. An increase in PWV of 0.15 m per second or more, a previously defined annual rate in individuals of similar age, was also assessed as a secondary end point. RESULTS: Of the 300 participants (150 randomized to atorvastatin and 150 randomized to placebo), 152 (mean [SD] age, 51 [17] years; 72 female [47%]; 82 treated with atorvastatin) had paired PWV data, and 168 had paired AD data. The PWV values remained similar in the atorvastatin group (mean [SD], 6.5 [1.9] vs 6.5 [2.0] m per second) but increased in the placebo group (5.7 [1.8] vs 6.8 [2.0] m per second) over 12 months. A 1 SD or more increase (0.8 m per second) in PWV was observed among 4 of 82 patients (5%) with atorvastatin and 35 of 70 patients (50%) with placebo (odds ratio, 0.05; 95% CI, 0.02 to 0.16; P < .001) at 12 months. A 1 SD or more decrease (1.8 × 10-3 mm Hg-1) in AAD was observed among 6 of 88 patients (7%) with atorvastatin and in 14 of 80 patients (18%) with placebo. A 1 SD or more increase in PWV was associated with a mean left ventricular ejection fraction decline of 2.70% (95% CI, -4.65% to -0.81%; P = .006). CONCLUSIONS AND RELEVANCE: Pretreatment with atorvastatin was associated with preservation of vascular function among patients with lymphoma undergoing anthracycline-based chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02943590.
引用
- Juhasz V, Drobni ZD, Quinaglia T, et al. Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41205202. doi:10.1001/jamacardio.2025.4548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。